"Risk Assessment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
| Descriptor ID |
D018570
|
| MeSH Number(s) |
E05.318.740.600.800.715 N04.452.871.715 N05.715.360.750.625.700.690 N06.850.505.715 N06.850.520.830.600.800.715
|
| Concept/Terms |
Risk Assessment- Risk Assessment
- Assessments, Risk
- Risk Assessments
- Health Risk Assessment
- Assessment, Health Risk
- Assessments, Health Risk
- Health Risk Assessments
- Risk Assessment, Health
- Risk Assessments, Health
- Assessment, Risk
Benefit-Risk Assessment- Benefit-Risk Assessment
- Assessment, Benefit-Risk
- Assessments, Benefit-Risk
- Benefit Risk Assessment
- Benefit-Risk Assessments
- Risk-Benefit Assessment
- Assessment, Risk-Benefit
- Assessments, Risk-Benefit
- Risk Benefit Assessment
- Risk-Benefit Assessments
|
Below are MeSH descriptors whose meaning is more general than "Risk Assessment".
Below are MeSH descriptors whose meaning is more specific than "Risk Assessment".
This graph shows the total number of publications written about "Risk Assessment" by people in this website by year, and whether "Risk Assessment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 5 | 6 |
| 1997 | 2 | 5 | 7 |
| 1998 | 0 | 4 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 12 | 12 |
| 2001 | 1 | 22 | 23 |
| 2002 | 0 | 33 | 33 |
| 2003 | 2 | 51 | 53 |
| 2004 | 4 | 56 | 60 |
| 2005 | 2 | 58 | 60 |
| 2006 | 7 | 41 | 48 |
| 2007 | 10 | 64 | 74 |
| 2008 | 2 | 81 | 83 |
| 2009 | 6 | 83 | 89 |
| 2010 | 6 | 94 | 100 |
| 2011 | 3 | 146 | 149 |
| 2012 | 6 | 119 | 125 |
| 2013 | 6 | 114 | 120 |
| 2014 | 19 | 122 | 141 |
| 2015 | 19 | 109 | 128 |
| 2016 | 15 | 139 | 154 |
| 2017 | 21 | 152 | 173 |
| 2018 | 18 | 153 | 171 |
| 2019 | 31 | 158 | 189 |
| 2020 | 23 | 150 | 173 |
| 2021 | 16 | 107 | 123 |
| 2022 | 0 | 44 | 44 |
| 2023 | 0 | 54 | 54 |
| 2024 | 1 | 122 | 123 |
| 2025 | 0 | 126 | 126 |
| 2026 | 0 | 79 | 79 |
To return to the timeline,
click here.
Below are the most recent publications written about "Risk Assessment" by people in Profiles.
-
Social Risk Screening and Referrals in the Pediatric Inpatient Setting. Pediatrics. 2026 Nov 01; 158(5).
-
Correlation of the Distressed Communities Index Score With Cardiovascular Risk Factors and Disease in the United States. J Am Heart Assoc. 2026 Nov 03; 15(21):e048128.
-
Role of Plasma Proteins in the Association Between Socioeconomic Status and Cardiovascular Disease Events: Results From Trans-Omics for Precision Medicine Cohorts. J Am Heart Assoc. 2026 Nov 03; 15(21):e043751.
-
rVSV-?G-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2026 Dec 20; 94:129113.
-
Acute Coronary Occlusions in NSTEMI Undergoing Percutaneous Coronary Intervention: Insights From the CathPCI Registry. JACC Cardiovasc Interv. 2026 Oct 12; 19(19):2539-2551.
-
Polygenic Determinants of Arterial Stiffness: Implications for Hypertension. J Am Heart Assoc. 2026 Oct 20; 15(20):e047424.
-
Characterization of chemoresistant cell populations improves risk stratification and therapy prediction in pediatric acute myeloid leukemia. Nat Commun. 2026 Oct 02; 17(1).
-
Evaluating a Polygenic Risk Score for Hepatocellular Carcinoma in Multiethnic Cirrhosis Patients in Texas. Cancer Med. 2026 Oct; 15(10):e72375.
-
Using artificial intelligence to identify drowning risk and protective factors present in media reports in metropolitan Houston, Texas. Inj Prev. 2026 Sep 28; 32(5):883-885.
-
Bayesian personalized dose constraints in selecting patients with non-small cell lung cancer for cardiac risk-adaptive treatment. Radiother Oncol. 2026 Nov; 224:111775.